RxDoctor Payments Data

Lillie Cutugno, PA

Physician Assistant · Sewell, NJNPI 1306543053

Payments from drug & device makers

$4,617in general payments, 2019–2025

Across 284 payments — averaging $16.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$1K
  • Amgen$709
  • AstraZeneca$291
  • Novartis$226
  • UCB, Inc.$184
  • plus $593 from 15 others

What the payments were for

  • Food & beverage$4,29293%
  • Education$3257%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,617 in reported general payments places this provider in the 90th percentile of 2,726 physician assistant providers in New Jersey.

See all physician assistant providers in New Jersey

Medicare billing

Part B allowed, 2024
$588,975
Medicare patients
394
Services billed
54,308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cimzia (2 Pack)Certolizumab Pegol31$189,402
Cosentyx Sensoready PenSecukinumab11$139,249
Humira(Cf) PenAdalimumab16$122,619
Enbrel SureclickEtanercept13$95,426
BenlystaBelimumab12$43,490
ProliaDenosumab23$41,308
Hydroxychloroquine Sulfate195$8,577
MethotrexateMethotrexate Sodium160$4,942
Colchicine30$4,877
Cevimeline Hcl15$4,627
Celecoxib113$4,021
Pregabalin121$2,516
Lidocaine19$2,063
Diclofenac Sodium93$2,050
Gabapentin146$1,633

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Cimzia (2 Pack)$184$189,40231 claims
GSKBenlysta$27$43,49012 claims
AmgenProlia$709$41,30823 claims
Scilex Pharmaceuticals Inc.Colchicine$32$4,87730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,726 physician assistant providers in New Jersey.

Other physician assistant in Sewell

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →